Navigation Links
Halozyme Therapeutics Reports First Quarter 2011 Financial Results
Date:5/6/2011

for the first quarter of 2010. The decline for SG&A results from lower compensation and market research expenses during the quarter.  
  • Cash and cash equivalents were $73.8 million as of March 31, 2011, compared with $83.3 million as of December 31, 2010 and $55.2 million as of March 31, 2010. Net cash burn for the first quarter of 2011 was approximately $9.4 million.
  • For 2011, management anticipates total operating expenses will be slightly higher than those reported for 2010, which were approximately $68 million. The increase for operating expense is expected to arise from costs associated with additional activities related to clinical trials and manufacturing. The company continues to expect net cash burn of $47 to $52 million for the year 2011.

  • Upcoming Corporate and Scientific PresentationsHalozyme representatives are scheduled to present at the following events:

  • Bank of America Merrill Lynch Health Care Conference in Las Vegas, May 12, 2011 at 11:10 a.m. PDT (2:10 p.m. EDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. The replay will be available for six months after the event.
  • American Diabetes Association Scientific Sessions – June 24-28, 2011 in San Diego. Halozyme has been notified of acceptance for two presentations of results and data from its Ultrafast Insulin program.

  • Conference CallHalozyme management will host a conference call and webcast on May 6, 2011 to discuss these topics beginning at 8:00 a.m. PDT (11:00 a.m. EDT). To participate via telephone, please call 877.407.8037 for domestic callers or 201.689.8037 for international callers. A telephone replay will be available beginning shortly after the end of the call by dialing 877.660.6853 from the U.S. or 201.612.7415 for international callers and using account # 367 and
    '/>"/>

    SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    2. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    3. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    4. Halozyme Receives $5.5 Million Payment From Baxter
    5. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    6. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
    7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
    8. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    9. Halozyme Therapeutics to Host Research Day for Investors and Analysts
    10. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
    11. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... PETERSBURG, Russia , July 10, 2014 ... Russian Federation Dmitry Medvedev , presented ... biopharmaceutical company BIOCAD . The Company is developing ... scope of MabNext project BIOCAD develops a number of ... cancer and autoimmune diseases. The ceremony took place at ...
    (Date:7/10/2014)... PROVO, Utah , July 10, 2014 ... genome annotation and interpretation, today announced an ... sequencing (NGS) analytics for Lineagen,s NextStep Dx ... evaluation of neurodevelopmental and neurological disorders, currently ... chromosomal microarray (CMA) testing service used by ...
    (Date:7/10/2014)... 2014   Ceres, Inc . (Nasdaq: ... today financial results for the three months ended May ... Ceres reported that the company and its ... growing season in Brazil, which concluded in June, despite ... evaluation areas for part of the growing season. Yields ...
    (Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
    Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2
    ... Diagnostics, a leading developer of biofluid-based molecular diagnostic ... the appointment of David Okrongly, Ph.D., as chief ... medical officer, and Sally Bowden, Ph.D., as director ... of cardiothoracic surgery Harvard University and Michael Manyak, ...
    ... Glioblastoma is one of the most aggressive forms ... tumor, glioblastoma will often infiltrate the surrounding brain tissue, ... chemotherapy or radiation. Likewise, several mouse models of glioblastoma ... a new study, a team led by scientists at ...
    ... announced today the launch of Curve™ Image Guided Surgery. ... surgery, is unveiling at the Congress of Neurological Surgeons ... of enhancements based on years of feedback from our ... for Brainlab and has helped to produce the ultimate ...
    Cached Biology Technology:Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 2Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 3Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 4Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 5Nanoparticles seek and destroy glioblastoma in mice 2Nanoparticles seek and destroy glioblastoma in mice 3Brainlab Launches Newest Innovation in Image Guided Surgery Technology 2Brainlab Launches Newest Innovation in Image Guided Surgery Technology 3
    (Date:7/13/2014)... more effective treatments for cachexia, a profound wasting of ... cancer patients, raising their risk of death, according to ... been tried to reverse the condition, which may cause ... but none have had great success. , Scientists reporting ... Nature , led by Bruce Spiegelman, PhD, demonstrated that ...
    (Date:7/11/2014)... the City of Entiat on Tuesday, July 8, 2014. ... grew to over 1,000 acres by evening. Three outbuildings ... investigation by the Washington Department of Natural Resources. The ... in developing fire control strategies and tactics. Other cooperators ... of Natural Resources, (WA DNR), Bureau of Land Management, ...
    (Date:7/11/2014)... scientists have set a "mouse TRAP" to capture the ... recent study published in the Journal of Clinical ... technique called TRAP to extract cellular and genetic information ... scientists at the Rockefeller Institute for Medical Research in ... protein-making machinery, or ribosomes, of the cell type of ...
    Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3
    ... River in Washington, D.C. is showing multiple benefits from ... improved water clarity have increased the abundance and diversity ... to direct measurements taken during the 18-year field study. ... the lower Potomac has doubled, the area covered by ...
    ... YORK, Sept. 7 Reportlinker.com announces that a new ... Biomarkers - technologies,markets and companies ... This report follows the broad definition of ... measured and evaluated as an indicator of normal biological ...
    ... 2009, newly installed photovoltaic (PV) cells world-wide produced a peak ... 5.8 GW was located in Europe. Similarly to previous years, ... of the world,s new solar systems were installed. By the ... (existing and newly installed) was 16 GW, which is about ...
    Cached Biology News:Potomac River: 10-fold increase in native submerged vegetation reflects improved water quality 2Reportlinker Adds Biomarkers - technologies, markets and companies 2Reportlinker Adds Biomarkers - technologies, markets and companies 3Reportlinker Adds Biomarkers - technologies, markets and companies 4Reportlinker Adds Biomarkers - technologies, markets and companies 5Reportlinker Adds Biomarkers - technologies, markets and companies 6Reportlinker Adds Biomarkers - technologies, markets and companies 7Reportlinker Adds Biomarkers - technologies, markets and companies 8Reportlinker Adds Biomarkers - technologies, markets and companies 9Reportlinker Adds Biomarkers - technologies, markets and companies 10Reportlinker Adds Biomarkers - technologies, markets and companies 11Reportlinker Adds Biomarkers - technologies, markets and companies 12Reportlinker Adds Biomarkers - technologies, markets and companies 13Reportlinker Adds Biomarkers - technologies, markets and companies 14Reportlinker Adds Biomarkers - technologies, markets and companies 15Reportlinker Adds Biomarkers - technologies, markets and companies 16Reportlinker Adds Biomarkers - technologies, markets and companies 17Reportlinker Adds Biomarkers - technologies, markets and companies 18Reportlinker Adds Biomarkers - technologies, markets and companies 19Reportlinker Adds Biomarkers - technologies, markets and companies 20Three-quarters of new solar systems worldwide were installed in the EU in 2009 2Three-quarters of new solar systems worldwide were installed in the EU in 2009 3
    BI-1 Polyclonal Antibody Storage Temperature: -20C Shipping: gel pack Shelf-Life: 12 months...
    ... cells of embryonal carcinoma of testis and ovary ... like seminoma. Glandular epithelium of yolk sac tumor ... cells of stomach and acini cells of pancreas ... Epitope: Carbohydrate portion on human embryonal carcinoma ...
    ... Endothelin-1 (human, porcine) Endogenous potent ... ETA receptor and modulates vascular tonus. ET-1, ... three distinct endothelin genes. ET-2 and ET-3 ... two and six amino acids, respectively. All ...
    HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
    Biology Products: